Skip to Main Content
Welcome to theĀ Scientist.comĀ Marketplace

Go to Main Navigation

BP7553b

SRPK2 Antibody (C-term) Blocking Peptide

Abcepta

DETAILS

  • Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
  • Gene Id: 6733
  • Category: Peptides; Blocking Peptides
  • Subtitle: Synthetic peptide
  • Gene Name: SRPK2
  • Other Names: SRSF protein kinase 2, SFRS protein kinase 2, Serine/arginine-rich protein-specific kinase 2, SR-protein-specific kinase 2, SRSF protein kinase 2 N-terminal, SRSF protein kinase 2 C-terminal, SRPK2 {ECO:0000312|EMBL:AAH685471}
  • Availability: 2 weeks
  • Bio Background: Protein kinases are enzymes that transfer a phosphate group from a phosphate donor, generally the g phosphate of ATP, onto an acceptor amino acid in a substrate protein. By this basic mechanism, protein kinases mediate most of the signal transduction in eukaryotic cells, regulating cellular metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell movement, apoptosis, and differentiation. With more than 500 gene products, the protein kinase family is one of the largest families of proteins in eukaryotes. The family has been classified in 8 major groups based on sequence comparison of their tyrosine (PTK) or serine/threonine (STK) kinase catalytic domains. The STE group (homologs of yeast Sterile 7, 11, 20 kinases) consists of 50 kinases related to the mitogen-activated protein kinase (MAPK) cascade families (Ste7/MAP2K, Ste11/MAP3K, and Ste20/MAP4K). MAP kinase cascades, consisting of a MAPK and one or more upstream regulatory kinases (MAPKKs) have been best characterized in the yeast pheromone response pathway. Pheromones bind to Ste cell surface receptors and activate yeast MAPK pathway.
  • Bio References: Blume-Jensen P, et al. Nature 2001. 411: 355.Cantrell D, J. Cell Sci. 2001. 114: 1439.Jhiang S Oncogene 2000. 19: 5590.Manning G, et al. Science 2002. 298: 1912.Moller, D, et al. Am. J. Physiol. 1994. 266: C351-C359.Robertson, S. et al. Trends Genet. 2000. 16: 368.Robinson D, et al. Oncogene 2000. 19: 5548.Van der Ven, P, et al. Hum. Molec. Genet. 1993. 2: 1889.Vanhaesebroeck, B, et al. Biochem. J. 2000. 346: 561.Van Weering D, et al. Recent Results Cancer Res. 1998. 154: 271.
  • Primary Accession: P78362
  • Targetspecificity: The synthetic peptide sequence used to generate the antibody AP7553b was selected from the C-term region of human SRPK2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.